Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings
31 5월 2008 - 7:46AM
PR Newswire (US)
Trial Demonstrates Safety and Preliminary Efficacy and Supports
Further Clinical Development of tgAAC94 BOSTON and SEATTLE, May 30
/PRNewswire-FirstCall/ -- Targeted Genetics Corporation
(NASDAQ:TGEN) issued a news release earlier today, entitled
"Targeted Genetics Reports Additional Data From Inflammatory
Arthritis Clinical Trial," announcing additional interim data from
its Phase 1/2 clinical study of tgAAC94 in patients with
inflammatory arthritis. Pervin Anklesaria, Ph.D., vice president of
therapeutic development for Targeted Genetics, presented the data
in an oral presentation at the 11th Annual Meeting of the American
Society of Gene Therapy (ASGT) in Seattle. To clarify, the data
demonstrated that a 30 percent decrease in the global visual analog
scale (VAS) was experienced by 21/50 (42 percent) of subjects and
3/16 (19 percent) placebo subjects 12 weeks after the first
injection. The global VAS is a clinically meaningful and commonly
used pain assessment tool to help patients describe the intensity
of their pain. A two-point decrease in swelling was noted in 8/50
(16 percent) treated subjects and 3/16 (19 percent) placebo
subjects 12 weeks after the first injection. It appears that the
patient-reported outcome measures of clinical response yielded
greater differentiation between tgAAC94 and placebo than physical
examination. In a subset of subjects, MRI was also performed on
treated joints and a decrease in effusion was noted in 1/10
subjects tested. "We are very pleased that the trial met safety
endpoints and demonstrated preliminary efficacy," said H. Stewart
Parker, president and chief executive officer of Targeted Genetics.
"We believe the data suggest that tgAAC94 has the potential to
improve disease symptoms that are refractory to other therapies,
including systemic TNF antagonists." Patients in this Phase 1/2
study continue to be followed for safety and measures aimed to
assess functional improvement in treated joints. About Targeted
Genetics Corporation Targeted Genetics Corporation is a
biotechnology company committed to the development of innovative
targeted molecular therapies for the prevention and treatment of
acquired and inherited diseases with significant unmet medical
need. Targeted Genetics' proprietary Adeno-Associated Virus (AAV)
technology platform allows it to deliver genes that encode proteins
to increase gene function or RNAi to decrease or silence gene
function. Targeted Genetics' product development efforts target
inflammatory arthritis, AIDS prophylaxis, congestive heart failure
and Huntington's disease. To learn more about Targeted Genetics,
visit Targeted Genetics' website at
http://www.targetedgenetics.com/. Safe Harbor Statement under the
Private Securities Litigation Reform Act of 1995: This release
contains forward-looking statements regarding the Company's
business strategy and product development, including statements
regarding the data collected in the inflammatory arthritis study,
the potential efficacy of tgAAC94, the potential impact of the
study on our results of operations and other statements about the
Company's plans, objectives, intentions and expectations. These
statements involve current expectations, forecasts of future events
and other statements that are not historical facts. Inaccurate
assumptions and known and unknown risks and uncertainties can
affect the accuracy of forward-looking statements. Factors that
could affect actual future events or results include, but are not
limited to, payments anticipated by the Company under product
development collaborations and contracts, the Company's actual
expenses, the Company's ability to raise capital when needed, the
timing, nature and results of the Company's clinical trials,
potential development of alternative technologies or more effective
products by competitors, the Company's ability to obtain and
maintain regulatory or institutional approvals, the Company's
ability to maintain its listing on the NASDAQ Capital Market and
the Company's ability to obtain, maintain and protect its
intellectual property, as well as other risk factors described in
its filings with the Securities and Exchange Commission (SEC),
including in "Item 1A. Risk Factors" in the Company's most recent
quarterly report on Form 10-Q for the quarter ended March 31, 2008
filed with the SEC. You should not rely unduly on these
forward-looking statements, which apply only as of the date of this
release. The Company undertakes no duty to publicly announce or
report revisions to these statements as new information becomes
available that may change the Company's expectations. DATASOURCE:
Targeted Genetics Corporation CONTACT: investors and media, Stacie
D. Byars, +1-415-946-1072, or Carolyn Wang, +1-415-946-1065, both
of WeissComm Partners, for Targeted Genetics Corporation Web site:
http://www.targetedgenetics.com/
Copyright
Tecogen (NASDAQ:TGEN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Tecogen (NASDAQ:TGEN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024